This study provides a starting point for further studies aimed at understanding the molecular mechanisms that distinguish the 5-LOX pathway inhibitors from BTKi as well as assessing whether 5-LOX inhibitors might be a potential treatment of CLL. The gene discussed is ALOX5; the disease is B-cell chronic lymphocytic leukemia.